Liver injury is independently associated with adverse clinical outcomes in patients with COVID-19
© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ..
OBJECTIVE: Data on serial liver biochemistries of patients infected by different human coronaviruses (HCoVs) are lacking. The impact of liver injury on adverse clinical outcomes in coronavirus disease 2019 (COVID-19) patients remains unclear.
DESIGN: This was a retrospective cohort study using data from a territory-wide database in Hong Kong. COVID-19, severe acute respiratory syndrome (SARS) and other HCoV patients were identified by diagnosis codes and/or virological results. Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) elevation was defined as ALT/AST ≥2 × upper limit of normal (ie, 80 U/L). The primary end point was a composite of intensive care unit (ICU) admission, use of invasive mechanical ventilation and/or death.
RESULTS: We identified 1040 COVID-19 patients (mean age 38 years, 54% men), 1670 SARS patients (mean age 44 years, 44% men) and 675 other HCoV patients (mean age 20 years, 57% men). ALT/AST elevation occurred in 50.3% SARS patients, 22.5% COVID-19 patients and 36.0% other HCoV patients. For COVID-19 patients, 53 (5.1%) were admitted to ICU, 22 (2.1%) received invasive mechanical ventilation and 4 (0.4%) died. ALT/AST elevation was independently associated with primary end point (adjusted OR (aOR) 7.92, 95% CI 4.14 to 15.14, p<0.001) after adjusted for albumin, diabetes and hypertension. Use of lopinavir-ritonavir ±ribavirin + interferon beta (aOR 1.94, 95% CI 1.20 to 3.13, p=0.006) and corticosteroids (aOR 3.92, 95% CI 2.14 to 7.16, p<0.001) was independently associated with ALT/AST elevation.
CONCLUSION: ALT/AST elevation was common and independently associated with adverse clinical outcomes in COVID-19 patients. Use of lopinavir-ritonavir, with or without ribavirin, interferon beta and/or corticosteroids was independently associated with ALT/AST elevation.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:70 |
---|---|
Enthalten in: |
Gut - 70(2021), 4 vom: 31. Apr., Seite 733-742 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Yip, Terry Cheuk-Fung [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 15.03.2021 Date Revised 29.08.2023 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1136/gutjnl-2020-321726 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM312187661 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM312187661 | ||
003 | DE-627 | ||
005 | 20231225143856.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1136/gutjnl-2020-321726 |2 doi | |
028 | 5 | 2 | |a pubmed24n1040.xml |
035 | |a (DE-627)NLM312187661 | ||
035 | |a (NLM)32641471 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Yip, Terry Cheuk-Fung |e verfasserin |4 aut | |
245 | 1 | 0 | |a Liver injury is independently associated with adverse clinical outcomes in patients with COVID-19 |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 15.03.2021 | ||
500 | |a Date Revised 29.08.2023 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ. | ||
520 | |a OBJECTIVE: Data on serial liver biochemistries of patients infected by different human coronaviruses (HCoVs) are lacking. The impact of liver injury on adverse clinical outcomes in coronavirus disease 2019 (COVID-19) patients remains unclear | ||
520 | |a DESIGN: This was a retrospective cohort study using data from a territory-wide database in Hong Kong. COVID-19, severe acute respiratory syndrome (SARS) and other HCoV patients were identified by diagnosis codes and/or virological results. Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) elevation was defined as ALT/AST ≥2 × upper limit of normal (ie, 80 U/L). The primary end point was a composite of intensive care unit (ICU) admission, use of invasive mechanical ventilation and/or death | ||
520 | |a RESULTS: We identified 1040 COVID-19 patients (mean age 38 years, 54% men), 1670 SARS patients (mean age 44 years, 44% men) and 675 other HCoV patients (mean age 20 years, 57% men). ALT/AST elevation occurred in 50.3% SARS patients, 22.5% COVID-19 patients and 36.0% other HCoV patients. For COVID-19 patients, 53 (5.1%) were admitted to ICU, 22 (2.1%) received invasive mechanical ventilation and 4 (0.4%) died. ALT/AST elevation was independently associated with primary end point (adjusted OR (aOR) 7.92, 95% CI 4.14 to 15.14, p<0.001) after adjusted for albumin, diabetes and hypertension. Use of lopinavir-ritonavir ±ribavirin + interferon beta (aOR 1.94, 95% CI 1.20 to 3.13, p=0.006) and corticosteroids (aOR 3.92, 95% CI 2.14 to 7.16, p<0.001) was independently associated with ALT/AST elevation | ||
520 | |a CONCLUSION: ALT/AST elevation was common and independently associated with adverse clinical outcomes in COVID-19 patients. Use of lopinavir-ritonavir, with or without ribavirin, interferon beta and/or corticosteroids was independently associated with ALT/AST elevation | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a cholestasis | |
650 | 4 | |a hepatitis | |
650 | 4 | |a liver function test | |
650 | 7 | |a Adrenal Cortex Hormones |2 NLM | |
650 | 7 | |a Antiviral Agents |2 NLM | |
650 | 7 | |a Drug Combinations |2 NLM | |
650 | 7 | |a lopinavir-ritonavir drug combination |2 NLM | |
650 | 7 | |a Lopinavir |2 NLM | |
650 | 7 | |a 2494G1JF75 |2 NLM | |
650 | 7 | |a Ribavirin |2 NLM | |
650 | 7 | |a 49717AWG6K |2 NLM | |
650 | 7 | |a Aspartate Aminotransferases |2 NLM | |
650 | 7 | |a EC 2.6.1.1 |2 NLM | |
650 | 7 | |a Alanine Transaminase |2 NLM | |
650 | 7 | |a EC 2.6.1.2 |2 NLM | |
650 | 7 | |a Ritonavir |2 NLM | |
650 | 7 | |a O3J8G9O825 |2 NLM | |
700 | 1 | |a Lui, Grace Chung-Yan |e verfasserin |4 aut | |
700 | 1 | |a Wong, Vincent Wai-Sun |e verfasserin |4 aut | |
700 | 1 | |a Chow, Viola Chi-Ying |e verfasserin |4 aut | |
700 | 1 | |a Ho, Tracy Hang-Yee |e verfasserin |4 aut | |
700 | 1 | |a Li, Timothy Chun-Man |e verfasserin |4 aut | |
700 | 1 | |a Tse, Yee-Kit |e verfasserin |4 aut | |
700 | 1 | |a Hui, David Shu-Cheong |e verfasserin |4 aut | |
700 | 1 | |a Chan, Henry Lik-Yuen |e verfasserin |4 aut | |
700 | 1 | |a Wong, Grace Lai-Hung |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Gut |d 1960 |g 70(2021), 4 vom: 31. Apr., Seite 733-742 |w (DE-627)NLM000003557 |x 1468-3288 |7 nnns |
773 | 1 | 8 | |g volume:70 |g year:2021 |g number:4 |g day:31 |g month:04 |g pages:733-742 |
856 | 4 | 0 | |u http://dx.doi.org/10.1136/gutjnl-2020-321726 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 70 |j 2021 |e 4 |b 31 |c 04 |h 733-742 |